Vol. 8, Issue 1, Part A (2026)

The coronavirus (COVID-19) is an enveloped RNA virus with varied origins in humans and wildlife. Six distinct species have been identified as the causative agents of human disease. Viral infections substantially affect human health, with the recent global epidemic being the introduction of the novel coronavirus. The SS-RNA virus belonging to the enveloped coronavirus family is responsible for the potentially fatal Severe Acute Respiratory Syndrome (SARS). In numerous countries worldwide, illness is proliferating rapidly. As of March 26, 2020, there have been 462,684 confirmed cases and 20,834 recorded fatalities internationally. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020. A multitude of pharmacological research are currently under progress, with several yielding favorable outcomes. The sole method to combat the virus is through preventative measures, as no immunization exists. The objective of the present work was to employ a molecular docking methodology to assess terpenoid derivatives as possible agents against SARS-CoV-2 infection. Clarification of the suggested mechanism of action of natural terpenoids (terpein-4-ol, terpinolene, and beta-sesquiphellandrene) in combating SAR-CoV-2 infection.